So many supportive care and therapeutics in phase 3. With BILLIONS in revenue potential.
I doubt PFE and MRK will let this one to get away. Can you say bidding war?
Easily reaches $100 on it's own.
Unknown Gem with Brutal Upside Potential.
Another 2 NDA filings and 2-3 Partnerships coming this Year ..Only 20 M on the float ..
IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Market Cap : $29 M
Cash: $3 M
Burn-Rate : $1.2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing later in 2013
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing later in 2013
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA filing later in 2013
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
Harry has posted a Charts of the Day video on TSRO at TheTechTrader site noting: Tesaro, Inc. (TSRO) had a great day on Monday, exploding 12.01, or 35%, on 1.5 million shares. It opened at 34.45, and got up to 47.50 before pulling back to 46.22, 15 points off the opening price. A nice day trade there and a very nice close. This stock hasn’t been public very long, yet reached a new all-time IPO high on Monday, having run from the 11 range all the way up to 47 just since September. This is another monster biotech stock.
thanks i will sell tommorow, thank you for your concern
Rolapitant is unlikely to ever achieve significant market acceptance, for numerous reasons we have outlined above. The rest of the pipeline is early stage and unproven. Wall Street has rightly discounted it greatly and assigns it almost no value. The Tesaro of 2015 will likely have one FDA approved drug with dim prospects of success in the CINV market, an uninspiring pipeline, and a greatly depleted treasury. Tesaro's fair value, as its prospectus initially warned, appears to be in the single digits, and we expect to see the stock trade there sooner or later.
this is the broker george he is usually on the money If you are long TSRO be warned
was this russell george of the irs, lol you should have listened to brian nichols of the motley fool and pearson from sa..